Atara Biotherapeutics, Inc. financial data

Symbol
ATRA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 105 % -74%
Quick Ratio 8.44 %
Debt-to-equity -418 % -414%
Return On Equity 387 %
Return On Assets -122 % -110%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 119 M shares +21.8%
Common Stock, Shares, Outstanding 120 M shares +24.6%
Entity Public Float 162 M USD -77.4%
Common Stock, Value, Issued 12 K USD +20%
Weighted Average Number of Shares Outstanding, Basic 141 M shares +35.2%
Weighted Average Number of Shares Outstanding, Diluted 141 M shares +35.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 208 M USD -19.9%
General and Administrative Expense 48.1 M USD -25.8%
Costs and Expenses 58.6 M USD -23.1%
Operating Income (Loss) -232 M USD +13.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -233 M USD -8.45%
Income Tax Expense (Benefit) 17 K USD -50%
Net Income (Loss) Attributable to Parent -233 M USD -8.44%
Earnings Per Share, Basic -2.12 USD/shares -1.44%
Earnings Per Share, Diluted -2.12 USD/shares -1.44%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.1 M USD -28%
Accounts Receivable, after Allowance for Credit Loss, Current 35.8 M USD +8926%
Inventory, Net 16.1 M USD +201%
Other Assets, Current 8.13 M USD -36.9%
Assets, Current 106 M USD -52.5%
Property, Plant and Equipment, Net 2.99 M USD -48.9%
Operating Lease, Right-of-Use Asset 52 M USD -20.2%
Other Assets, Noncurrent 3.87 M USD -44%
Assets 165 M USD -45.3%
Accounts Payable, Current 2.85 M USD -43.7%
Employee-related Liabilities, Current 5.71 M USD -36%
Accrued Liabilities, Current 18.2 M USD +169%
Contract with Customer, Liability, Current 77.8 M USD
Liabilities, Current 181 M USD +166%
Contract with Customer, Liability, Noncurrent 719 K USD -99.1%
Operating Lease, Liability, Noncurrent 42.2 M USD -23.2%
Other Liabilities, Noncurrent 4.4 M USD -15%
Liabilities 264 M USD +11.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -55 K USD +95.6%
Retained Earnings (Accumulated Deficit) -2 B USD -13.2%
Stockholders' Equity Attributable to Parent -98.3 M USD -251%
Liabilities and Equity 165 M USD -45.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.6 M USD +22.9%
Net Cash Provided by (Used in) Financing Activities 24.1 M USD +10173%
Net Cash Provided by (Used in) Investing Activities 14.7 M USD
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 120 M shares +24.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.2 M USD -27.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 114 K USD +1.79%
Deferred Tax Assets, Valuation Allowance 475 M USD +12.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 487 M USD +11.2%
Operating Lease, Liability 57 M USD -19.6%
Depreciation 3.7 M USD -9.76%
Payments to Acquire Property, Plant, and Equipment 127 K USD -68.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -232 M USD -8.22%
Lessee, Operating Lease, Liability, to be Paid 74.5 M USD -19.9%
Property, Plant and Equipment, Gross 19.7 M USD +3.11%
Operating Lease, Liability, Current 13.1 M USD +11.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 18.5 M USD +2.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 17.2 M USD -10.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +20.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 17.5 M USD -20.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 17.3 M USD -3.41%
Deferred Tax Assets, Operating Loss Carryforwards 324 M USD +6.94%
Current Income Tax Expense (Benefit) 15 K USD +25%
Preferred Stock, Shares Authorized 20 M shares 0%
Unrecognized Tax Benefits 160 M USD +6.21%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.76 M USD -65.2%
Operating Lease, Payments 16.7 M USD +24.2%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 1 K USD
Deferred Tax Assets, Net of Valuation Allowance 11.6 M USD -23.7%
Share-based Payment Arrangement, Expense 42 M USD -18%
Interest Expense 5.1 M USD +199%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares